IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Protein, Nutrition and Cardiovascular Disease in Stage 5 Chronic Kidney Disease
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
National Kidney Foundation guidelines recommend a dietary protein intake of 1.2 grams per kilogram per day (g/kg/d) in hemodialysis patients. However, it is unclear whether consumption of high amounts of protein in dialysis patients has beneficial or harmful nutritional and cardiovascular effects in this population. High protein intake might improve nutritional status, but it has been argued that the state of low muscle mass, small body size and low serum protein levels is not the result of decreased dietary intake, rather a result of hypercatabolism induced by metabolic acidosis, inflammation and oxidative stress.
The specific aims of this study are to examine in a prospective cohort of hemodialysis patients the longitudinal associations of absolute total protein intake or dietary protein intake with muscle mass and arterial stiffness.
| Condition |
|---|
| End Stage Renal Disease |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Protein Intake, Nutrition and Cardiovascular Disease in Stage 5 Chronic Kidney Disease (CKD) |
- Correlation of muscle mass with protein intake [ Time Frame: Baseline and 18 months ]Mid-thigh muscle mass measured by magnetic resonance imaging
- Correlation of arterial stiffness with protein intake [ Time Frame: Baseline and 18 months ]Radial artery stiffness measured by pulse wave velocity and pulse wave assessment
Biospecimen Retention: Samples With DNA
30 ml of blood drawn four times (months 1, 6, 12 and 18) for plasma/serum/DNA samples.
Urine Collection: If patients are making more than ½ cup (200 ml) of urine a day.
| Enrollment: | 145 |
| Study Start Date: | September 2007 |
| Study Completion Date: | October 2015 |
| Primary Completion Date: | October 2015 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
Observation (all participants)
Stage 5 Chronic Kidney Disease and hemodialysis patients
|
Detailed Description:
It is hypothesized that in the dialysis population overall: (1) Protein intake is a major determinant of muscle mass while inflammation, oxidative stress and metabolic acidosis play a lesser role; (2) Malnutrition is not an uremic cardiovascular risk factor hence low protein intake does not cause cardiovascular disease; and (3) In the other extreme, high protein intake is also not a major cause of cardiovascular disease since high serum phosphorus associated with high protein intake can usually be controlled by the use of phosphorus binders in routine clinical practice.
The specific aims of this proposal are to examine in a prospective cohort of hemodialysis patients the longitudinal associations of absolute total protein intake (TPI) in grams/day, or dietary protein intake (DPI) normalized to body weight in grams/kilogram/day) with
- Nutritional status (mid-thigh muscle mass as measured by Magnetic Resonance Imaging ) and functional status (6-min walk) and
- Arterial stiffness (aortic pulse wave velocity)
Understanding the relationship between protein intake with body composition (muscle mass) and intermediate cardiovascular outcomes (arterial stiffness) in stage 5 CKD patients in hemodialysis is of great scientific and practical significance
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Adult stage 5 chronic kidney disease patients, on dialysis for at least 3 months.
- Urine output > 200 mL/day
Exclusion Criteria:
- Patients with persistent volume overload (substantial pedal edema) despite attempts at achieving dry weight
- Patients with inability to walk or who use a wheel-chair with reduced mid-thigh muscle mass
- Persons with pacemakers, cochlear implants, or other prohibitive conditions for magnetic resonance imaging
- Atrial fibrillation
- Patients who are unlikely or unable (in the opinion of the nephrologists, nurses or dieticians taking care of the patient) to comply with research protocol
- Patients with symptomatic heart failure, current active malignancy (excluding squamous and basal cell skin cancers), active AIDS, chronic lung disease requiring supplemental oxygen therapy and cirrhosis
- Patients enrolled in interventional trials
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT00566670
| United States, Tennessee | |
| Vanderbilt University Medical Centet | |
| Nashville, Tennessee, United States, 37232-2372 | |
| United States, Utah | |
| University of Utah | |
| Salt Lake City, Utah, United States, 84112 | |
| Principal Investigator: | Srinivasan Beddhu, M.D | University of Utah |
More Information
| Responsible Party: | Srinvasan Beddhu, MD, University of Utah |
| ClinicalTrials.gov Identifier: | NCT00566670 History of Changes |
| Other Study ID Numbers: |
IRB_00024816 R01DK077298 ( U.S. NIH Grant/Contract ) |
| Study First Received: | November 29, 2007 |
| Last Updated: | August 9, 2016 |
Keywords provided by Srinvasan Beddhu, University of Utah:
|
Hemodialysis |
Additional relevant MeSH terms:
|
Cardiovascular Diseases Kidney Diseases Renal Insufficiency, Chronic |
Kidney Failure, Chronic Urologic Diseases Renal Insufficiency |
ClinicalTrials.gov processed this record on July 21, 2017